Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
peterschreiber.media Introduction In my previous article, I had a buy rating on Crispr Therapeutics (NASDAQ:CRSP). At the time, my arguments focused on the future potential of the CASGEVY program, which heavily relied on the success of the commercial …